RECRUITINGOBSERVATIONAL

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)

About This Trial

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice. Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide. Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Who May Be Eligible (Plain English)

Who May Qualify: - Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment. - Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines. - Decision to treat with risankizumab is made prior to and independently of study participation. Who Should NOT Join This Trial: - History of a sleep disorder diagnosis which the patient is currently being treated for. - Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study. - Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment. * Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines. * Decision to treat with risankizumab is made prior to and independently of study participation. Exclusion Criteria: * History of a sleep disorder diagnosis which the patient is currently being treated for. * Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study. * Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.

Locations (20)

Rejuvenation Dermatology - Edmonton Downtown /ID# 276688

Edmonton, Alberta, Canada

Winnipeg Clinic /ID# 276751

Winnipeg, Manitoba, Canada

Wiseman Dermatology Research /ID# 276847

Winnipeg, Manitoba, Canada

Cca Medical Research /ID# 276944

Ajax, Ontario, Canada

Quinte dermatology /ID# 277497

Belleville, Ontario, Canada

Dermatrials Research /ID# 276714

Hamilton, Ontario, Canada

Lovegrove Dermatology /ID# 276797

London, Ontario, Canada

Lynderm Research Inc /ID# 276755

Markham, Ontario, Canada

Rejuvenation Dermatology Clinic Oakville /ID# 277492

Oakville, Ontario, Canada

JRB Research inc. /ID# 277730

Ottawa, Ontario, Canada

Factor Dermatology /ID# 278610

Ottawa, Ontario, Canada

SKiN Centre for Dermatology /ID# 277594

Peterborough, Ontario, Canada

Eternal Springtime Dermatology /ID# 278598

Thunder Bay, Ontario, Canada

North York Research Inc /ID# 276835

Toronto, Ontario, Canada

Toronto Dermatology Centre /ID# 276846

Toronto, Ontario, Canada

Centre for Medical and Surgical Dermatology /ID# 278775

Whitby, Ontario, Canada

Dre Angelique Gagne-Henley M.D. inc. /ID# 276687

Saint-Jérôme, Quebec, Canada

Fakultní Nemocnice U Sv. Anny V Brně /ID# 275799

Brno, Brno-mesto, Czechia

Nemocnice Na Bulovce /ID# 275540

Prague, Central Bohemia, Czechia

Dermafit Centrum /ID# 275897

Pilsen, Plzeň Region, Czechia